著者

高根 浩

出版者

公益社団法人 日本薬学会

雑誌

YAKUGAKU ZASSHI (ISSN:00316903)

巻号頁・発行日

vol.131, no.11, pp.1589-1594, 2011-11-01 (Released:2011-11-01)

参考文献数

30

被引用文献数

4 8

---

Various drug transporters are selectively expressed in single or multiple tissues, such as the intestine, liver and kidney, where these transporters play various roles in drug absorption, distribution and excretion. Genetic polymorphisms in drug transporters as well as drug-metabolizing enzymes are associated with interindividual differences in drug disposition, efficacy and toxicity. Organic anion transporting polypeptide 1B1 (OATP1B1, gene SLCO1B1) is expressed on the basolateral membrane of hepatocytes and can facilitate hepatic uptake of certain clinically relevant drugs such as statins except for fluvastatin, angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, antidiabetic drug (repaglinide) and anticancer drugs (SN-38 and methotrexate). Some single nucleotide polymorphisms or haplotypes of the SLCO1B1 gene have been identified and demonstrated to have functional significance for transporter activity. For examples, the SLCO1B1*15 haplotype (or 521T>C genotype) results in decreased uptake activity of SN-38 from systemic circulation, leading to increased plasma concentration of SN-38 and an enhanced risk of neutropenia. This review focuses on the impact of genetic polymorphisms of the SLCO1B1 gene on transport activity, and implications for the clinical efficacy and toxicity of clinically useful drugs.

著者

金田 達也 大谷 誠司 高根 浩 椎木 芳和 林原 正和 大坪 健司

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.37, no.3, pp.187-193, 2011 (Released:2012-04-25)

参考文献数

9

被引用文献数

2 2

---

To ensure the proper use of drugs,pharmacists must pay attention to drug incompatibility information.However,drug incompatibilityinformation relating to tablets or capsules in one-dose packages (DII) is not well understood.Therefore,weactively collected DII and shared it with Tottori West District pharmacists and investigated how they currently dispensedone-dose packages as well as their degree of understanding of DII.For sharing,we selected 3 combinations of one-dosepackage including the olmesartan medoxomil(OM)-metformin hydrochloride (MET) combination for which incompatibilityhad actually been reported in our area.Before sharing DII,hardly any of the pharmacists knew about such information inthe package inserts,suggesting that it was not widely available to them.Our sharing of DII enhanced understanding of itfor all combinations.Also,the dispensing of one-dose packages was improved in many hospitals and community pharmacies.This suggestedthat the active collection of DII and its sharing by pharmacists helped ensure proper drug use.However,we should shareDII continuously to achieve a thorough understanding of it and additional methods may be required (for example,makingpresentations at meetings) for this purpose.We should also actively collect DII because the DII in package inserts is insufficientto ensure proper drug use.